vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2022-4-24-38vtio-1567Research ArticleКлиническая трансплантологияClinical TransplantologyРиски и пути профилактики нарушения функции почек при проведении медикаментозной иммуносупрессии у реципиентов солидных органовRisks and ways of preventing kidney dysfunction in drug-induced immunosuppression in solid organ recipientsГалеевШ. Р.GaleevSh. R.

Галеев Шамиль Ринатович

404120, Волжский, Волгоградская область, ул. Генерала Карбышева, д. 86

Тел. (917) 237-16-50

Shamil Galeev

86, Generala Karbysheva str., Volzhskiy, 404120, Russian Federation

Phone: (917) 237-16-50

namerec_taor_su@outlook.comГотьеС. В.GautierS. V.

Москва

Moscow

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian FederationФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский университет)РоссияShumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov UniversityRussian Federation2022201020222442438Copyright © Галеев Ш.Р., Готье С.В., 20222022Галеев Ш.Р., Готье С.В.Galeev S.R., Gautier S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1567

Иммуносупрессивная терапия (ИТ) является наиболее важным компонентом медикаментозного лечения после трансплантации. Задачей иммуносупрессии является предотвращение острого и хронического отторжения при достижении максимальной выживаемости пациента и долгосрочной функции трансплантата. Однако ожидаемые эффекты иммуносупрессивной терапии должны находиться в балансе с серьезными побочными эффектами этих препаратов и их токсичностью. Целью данного обзора было обобщение мирового опыта современной стратегии иммуносупрессии, оценка ее влияния на почечную функцию.

Immunosuppressive therapy (IMT) is the cornerstone of treatment after transplantation. The goal of immunosuppression is to prevent acute and chronic rejection while maximizing patient survival and long-term graft function. However, the expected effects of IMT must be balanced against the major adverse effects of these drugs and their toxicity. The purpose of this review is to summarize world experience on current immunosuppressive strategies and to assess their effects on renal function.

трансплантация органовиндукционная терапияиммуносупрессивная терапиянежелательные явленияпочечная недостаточностьorgan transplantationinduction therapyimmunosuppressive therapyadverse eventsrenal failureReferencesMetalidis C, Kuypers D. Immunosuppressive therapy after kidney transplantation: current and new strategies. Minerva Urol Nefrol. 2011 Mar; 63 (1): 1–19. PMID: 21336242.Metalidis C, Kuypers D. Immunosuppressive therapy after kidney transplantation: current and new strategies. Minerva Urol Nefrol. 2011 Mar; 63 (1): 1–19. PMID: 21336242.Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 2020 Jun–Aug; 46–47: 101681. doi: 10.1016/j.bpg.2020.101681. Epub 2020 Sep 11. PMID: 33158467.Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 2020 Jun–Aug; 46–47: 101681. doi: 10.1016/j.bpg.2020.101681. Epub 2020 Sep 11. PMID: 33158467.Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10 (6): 1420–1427. doi: 10.1111/j.1600-6143.2010.03126.x. Epub 2010 May 10. PMID: 20486907; PMCID: PMC2891375.Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10 (6): 1420–1427. doi: 10.1111/j.1600-6143.2010.03126.x. Epub 2010 May 10. PMID: 20486907; PMCID: PMC2891375.Ruebner RL, Reese PP, Denburg MR, Abt PL, Furth SL. End-stage kidney disease after pediatric nonrenal solid organ transplantation. Pediatrics. 2013 Nov; 132 (5): e1319–e1326. doi: 10.1542/peds.2013-0904. Epub 2013 Oct 14. PMID: 24127468; PMCID: PMC3813394.Ruebner RL, Reese PP, Denburg MR, Abt PL, Furth SL. End-stage kidney disease after pediatric nonrenal solid organ transplantation. Pediatrics. 2013 Nov; 132 (5): e1319–e1326. doi: 10.1542/peds.2013-0904. Epub 2013 Oct 14. PMID: 24127468; PMCID: PMC3813394.Williams C, Borges K, Banh T, Vasilevska-Ristovska J, Chanchlani R, Ng VL et al. Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients. Am J Transplant. 2018 Jun; 18 (6): 1481–1488. doi: 10.1111/ajt.14638. Epub 2018 Feb 6. PMID: 29286569.Williams C, Borges K, Banh T, Vasilevska-Ristovska J, Chanchlani R, Ng VL et al. Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients. Am J Transplant. 2018 Jun; 18 (6): 1481–1488. doi: 10.1111/ajt.14638. Epub 2018 Feb 6. PMID: 29286569.LaRosa C, Glah C, Baluarte HJ, Meyers KE. Solidorgan transplantation in childhood: transitioning to adult health care. Pediatrics. 2011 Apr; 127 (4): 742–753. doi: 10.1542/peds.2010-1232. Epub 2011 Mar 7. PMID: 21382946.LaRosa C, Glah C, Baluarte HJ, Meyers KE. Solidorgan transplantation in childhood: transitioning to adult health care. Pediatrics. 2011 Apr; 127 (4): 742–753. doi: 10.1542/peds.2010-1232. Epub 2011 Mar 7. PMID: 21382946.Choudhry S, Dharnidharka VR, Castleberry CD, Goss CW, Simpson KE, Schechtman KB, Canter CE. End-stage renal disease after pediatric heart transplantation: A 25-year national cohort study. J Heart Lung Transplant. 2017 Oct 2: S1053–2498(17)32042-9. doi: 10.1016/j.healun.2017.09.027. Epub ahead of print. PMID: 29055603; PMCID: PMC5880747.Choudhry S, Dharnidharka VR, Castleberry CD, Goss CW, Simpson KE, Schechtman KB, Canter CE. End-stage renal disease after pediatric heart transplantation: A 25-year national cohort study. J Heart Lung Transplant. 2017 Oct 2: S1053–2498(17)32042-9. doi: 10.1016/j.healun.2017.09.027. Epub ahead of print. PMID: 29055603; PMCID: PMC5880747.Menon S, Pollack AH, Sullivan E, Murphy T, Smith J. Acute kidney injury and chronic kidney disease after non-kidney solid organ transplantation. Pediatr Transplant. 2020 Sep; 24 (6): e13753. doi: 10.1111/petr.13753. Epub 2020 Jun 4. PMID: 32497381.Menon S, Pollack AH, Sullivan E, Murphy T, Smith J. Acute kidney injury and chronic kidney disease after non-kidney solid organ transplantation. Pediatr Transplant. 2020 Sep; 24 (6): e13753. doi: 10.1111/petr.13753. Epub 2020 Jun 4. PMID: 32497381.Sigurjonsdottir VK, Chaturvedi S, Mammen C, Sutherland SM. Pediatric acute kidney injury and the subsequent risk for chronic kidney disease: is there cause for alarm? Pediatr Nephrol. 2018 Nov; 33 (11): 2047–2055. doi: 10.1007/s00467-017-3870-6. Epub 2018 Jan 26. PMID: 29374316.Sigurjonsdottir VK, Chaturvedi S, Mammen C, Sutherland SM. Pediatric acute kidney injury and the subsequent risk for chronic kidney disease: is there cause for alarm? Pediatr Nephrol. 2018 Nov; 33 (11): 2047–2055. doi: 10.1007/s00467-017-3870-6. Epub 2018 Jan 26. PMID: 29374316.Charbonney E, Saudan P, Triverio PA, Quinn K, Mentha G, Martin PY. Prognosis of acute kidney injury requiring renal replacement therapy in solid organ transplanted patients. Transpl Int. 2009 Nov; 22 (11): 1058–1063. doi: 10.1111/j.1432-2277.2009.00914.x. Epub 2009 Jul 13. PMID: 19624498.Charbonney E, Saudan P, Triverio PA, Quinn K, Mentha G, Martin PY. Prognosis of acute kidney injury requiring renal replacement therapy in solid organ transplanted patients. Transpl Int. 2009 Nov; 22 (11): 1058–1063. doi: 10.1111/j.1432-2277.2009.00914.x. Epub 2009 Jul 13. PMID: 19624498.Pham PT, Slavov C, Pham PC. Acute kidney injury after liver, heart, and lung transplants: dialysis modality, predictors of renal function recovery, and impact on survival. Adv Chronic Kidney Dis. 2009 Jul; 16 (4): 256–267. doi: 10.1053/j.ackd.2009.04.002. PMID: 19576556.Pham PT, Slavov C, Pham PC. Acute kidney injury after liver, heart, and lung transplants: dialysis modality, predictors of renal function recovery, and impact on survival. Adv Chronic Kidney Dis. 2009 Jul; 16 (4): 256–267. doi: 10.1053/j.ackd.2009.04.002. PMID: 19576556.Nadkarni GN, Chauhan K, Patel A, Saha A, Poojary P, Kamat S et al. Temporal trends of dialysis requiring acute kidney injury after orthotopic cardiac and liver transplant hospitalizations. BMC Nephrol. 2017 Jul 19; 18 (1): 244. doi: 10.1186/s12882-017-0657-8. PMID: 28724404; PMCID: PMC5516358.Nadkarni GN, Chauhan K, Patel A, Saha A, Poojary P, Kamat S et al. Temporal trends of dialysis requiring acute kidney injury after orthotopic cardiac and liver transplant hospitalizations. BMC Nephrol. 2017 Jul 19; 18 (1): 244. doi: 10.1186/s12882-017-0657-8. PMID: 28724404; PMCID: PMC5516358.Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant. 2006 Apr; 6 (4): 671–679. doi: 10.1111/j.1600-6143.2006.01248.x. PMID: 16539623.Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant. 2006 Apr; 6 (4): 671–679. doi: 10.1111/j.1600-6143.2006.01248.x. PMID: 16539623.Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27; 72 (12): 1934–1939. doi: 10.1097/00007890-200112270-00012. PMID: 11773892.Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001 Dec 27; 72 (12): 1934–1939. doi: 10.1097/00007890-200112270-00012. PMID: 11773892.Beckebaum S, Cicinnati VR, Radtke A, Kabar I. Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors? Liver Int. 2013 May; 33 (5): 656–665. doi: 10.1111/liv.12133. Epub 2013 Feb 27. PMID: 23442173.Beckebaum S, Cicinnati VR, Radtke A, Kabar I. Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors? Liver Int. 2013 May; 33 (5): 656–665. doi: 10.1111/liv.12133. Epub 2013 Feb 27. PMID: 23442173.Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol. 2007 Jul; 27 (4): 498–507. doi: 10.1016/j.semnephrol.2007.03.010. PMID: 17616280.Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol. 2007 Jul; 27 (4): 498–507. doi: 10.1016/j.semnephrol.2007.03.010. PMID: 17616280.Nowicki M, Zwiech R. Chronic renal failure in non-renal organ transplant recipients. Ann Transplant. 2005; 10 (3): 54–58. PMID: 16617670.Nowicki M, Zwiech R. Chronic renal failure in non-renal organ transplant recipients. Ann Transplant. 2005; 10 (3): 54–58. PMID: 16617670.Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011 Jul; 24 (7): 640–650. doi: 10.1111/j.1432-2277.2011.01250.x. Epub 2011 Mar 23. PMID: 21429047.Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011 Jul; 24 (7): 640–650. doi: 10.1111/j.1432-2277.2011.01250.x. Epub 2011 Mar 23. PMID: 21429047.Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010 Dec 27; 90 (12): 1511–1515. doi: 10.1097/TP.0b013e3181fecfcb. PMID: 21057388.Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010 Dec 27; 90 (12): 1511–1515. doi: 10.1097/TP.0b013e3181fecfcb. PMID: 21057388.Levitsky J, O’Leary JG, Asrani S, Sharma P, Fung J, Wiseman A, Niemann CU. Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016 Sep; 16 (9): 2532–2544. doi: 10.1111/ajt.13765. Epub 2016 Apr 22. PMID: 26932352; PMCID: PMC5007154.Levitsky J, O’Leary JG, Asrani S, Sharma P, Fung J, Wiseman A, Niemann CU. Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016 Sep; 16 (9): 2532–2544. doi: 10.1111/ajt.13765. Epub 2016 Apr 22. PMID: 26932352; PMCID: PMC5007154.Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S et al. Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study. Transplant Direct. 2019 Aug 8; 5 (9): e480. doi: 10.1097/TXD.0000000000000917. PMID: 31579808; PMCID: PMC6739043.Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S et al. Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study. Transplant Direct. 2019 Aug 8; 5 (9): e480. doi: 10.1097/TXD.0000000000000917. PMID: 31579808; PMCID: PMC6739043.Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P et al. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl. 2008 Feb; 14 (2): 202–209. doi: 10.1002/lt.21348. PMID: 18236395.Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P et al. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl. 2008 Feb; 14 (2): 202–209. doi: 10.1002/lt.21348. PMID: 18236395.Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E et al. De novo sirolimus and reduceddose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000–2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14 (2): 356–366. doi: 10.1111/ajt.12543. Epub 2014 Jan 23. PMID: 24456026.Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E et al. De novo sirolimus and reduceddose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000–2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14 (2): 356–366. doi: 10.1111/ajt.12543. Epub 2014 Jan 23. PMID: 24456026.Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C et al. Spare-the-Nephron Trial Liver Transplantation Study Group. Calcineurin inhibitorfree mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013 Jul; 19 (7): 675–689. doi: 10.1002/lt.23658. PMID: 23775875.Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C et al. Spare-the-Nephron Trial Liver Transplantation Study Group. Calcineurin inhibitorfree mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013 Jul; 19 (7): 675–689. doi: 10.1002/lt.23658. PMID: 23775875.Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P et al. H2304 Study Group. Threeyear Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99 (7): 1455–1462. doi: 10.1097/TP.0000000000000555. PMID: 26151607.Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P et al. H2304 Study Group. Threeyear Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99 (7): 1455–1462. doi: 10.1097/TP.0000000000000555. PMID: 26151607.Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016 Jun; 30 (6): 741–748. doi: 10.1111/ctr.12744. Epub 2016 May 10. PMID: 27160359.Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016 Jun; 30 (6): 741–748. doi: 10.1111/ctr.12744. Epub 2016 May 10. PMID: 27160359.Lin M, Mittal S, Sahebjam F, Rana A, Sood GK. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. Clin Transplant. 2017 Feb; 31 (2). doi: 10.1111/ctr.12872. Epub 2017 Jan 18. PMID: 27862340.Lin M, Mittal S, Sahebjam F, Rana A, Sood GK. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. Clin Transplant. 2017 Feb; 31 (2). doi: 10.1111/ctr.12872. Epub 2017 Jan 18. PMID: 27862340.Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 May; 102 (5): 727–743. doi: 10.1097/TP.0000000000002147. Erratum in: Transplantation. 2019 Jan; 103 (1): e37. PMID: 29485508.Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 May; 102 (5): 727–743. doi: 10.1097/TP.0000000000002147. Erratum in: Transplantation. 2019 Jan; 103 (1): e37. PMID: 29485508.De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol. 2017 Apr; 31 (2): 199–209. doi: 10.1016/j.bpg.2017.03.001. Epub 2017 Apr 12. PMID: 28624108.De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol. 2017 Apr; 31 (2): 199–209. doi: 10.1016/j.bpg.2017.03.001. Epub 2017 Apr 12. PMID: 28624108.Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014 Aug; 14 (8): 1817–1827. doi: 10.1111/ajt.12810. PMID: 25041339; PMCID: PMC4140547.Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014 Aug; 14 (8): 1817–1827. doi: 10.1111/ajt.12810. PMID: 25041339; PMCID: PMC4140547.Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E et al. Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar; 12 (3): 694–705. doi: 10.1111/j.1600-6143.2011.03919.x. Epub 2012 Jan 10. PMID: 22233522.Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E et al. Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar; 12 (3): 694–705. doi: 10.1111/j.1600-6143.2011.03919.x. Epub 2012 Jan 10. PMID: 22233522.De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009 Oct; 15 (10): 1262–1269. doi: 10.1002/lt.21827. PMID: 19790150.De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009 Oct; 15 (10): 1262–1269. doi: 10.1002/lt.21827. PMID: 19790150.Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011 Aug; 17 (8): 905–913. doi: 10.1002/lt.22292. PMID: 21384525.Saliba F, Dharancy S, Lorho R, Conti F, Radenne S, Neau-Cransac M et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011 Aug; 17 (8): 905–913. doi: 10.1002/lt.22292. PMID: 21384525.Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castroagudín J, Fabregat J et al. EVEROLIVER study group. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transpl. 2015 Aug; 21 (8): 1056–1065. doi: 10.1002/lt.24172. PMID: 25990257.Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castroagudín J, Fabregat J et al. EVEROLIVER study group. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transpl. 2015 Aug; 21 (8): 1056–1065. doi: 10.1002/lt.24172. PMID: 25990257.Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, Obed A. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. Am J Transplant. 2012 Oct; 12 (10): 2601–2607. doi: 10.1111/j.1600-6143.2012.04157.x. Epub 2012 Jul 19. PMID: 22813081.Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, Obed A. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. Am J Transplant. 2012 Oct; 12 (10): 2601–2607. doi: 10.1111/j.1600-6143.2012.04157.x. Epub 2012 Jul 19. PMID: 22813081.Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012 Jan 18; 307 (3): 283–293. doi: 10.1001/jama.2011.2014. PMID: 22253395.Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012 Jan 18; 307 (3): 283–293. doi: 10.1001/jama.2011.2014. PMID: 22253395.Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013 Nov; 58 (5): 1824–1835. doi: 10.1002/hep.26426. Epub 2013 Sep 19. PMID: 23532679.Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013 Nov; 58 (5): 1824–1835. doi: 10.1002/hep.26426. Epub 2013 Sep 19. PMID: 23532679.Shaked A, DesMarais MR, Kopetskie H, Feng S, Punch JD, Levitsky J et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant. 2019 May; 19 (5): 1397–1409. doi: 10.1111/ajt.15205. Epub 2018 Dec 31. Erratum in: Am J Transplant. 2019 Aug; 19 (8): 2393. PMID: 30506630; PMCID: PMC6482056.Shaked A, DesMarais MR, Kopetskie H, Feng S, Punch JD, Levitsky J et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant. 2019 May; 19 (5): 1397–1409. doi: 10.1111/ajt.15205. Epub 2018 Dec 31. Erratum in: Am J Transplant. 2019 Aug; 19 (8): 2393. PMID: 30506630; PMCID: PMC6482056.Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal. 2007 Mar 9; 5: e003. doi: 10.1621/nrs.05003. PMID: 17464358; PMCID: PMC1853070.Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal. 2007 Mar 9; 5: e003. doi: 10.1621/nrs.05003. PMID: 17464358; PMCID: PMC1853070.Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004 Oct 1; 500 (1–3): 51–62. doi: 10.1016/j.ejphar.2004.07.011. PMID: 15464020.Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004 Oct 1; 500 (1–3): 51–62. doi: 10.1016/j.ejphar.2004.07.011. PMID: 15464020.Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004; 1 (3): 255–263. doi: 10.1513/pats.200402-015MS. PMID: 16113443.Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004; 1 (3): 255–263. doi: 10.1513/pats.200402-015MS. PMID: 16113443.Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study. Exp Clin Transplant. 2011 Apr; 9 (2): 121–127. PMID: 21453230.Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study. Exp Clin Transplant. 2011 Apr; 9 (2): 121–127. PMID: 21453230.Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation. 2001 Dec 27; 72 (12 Suppl): S75–80. PMID: 11833145.Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation. 2001 Dec 27; 72 (12 Suppl): S75–80. PMID: 11833145.Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999 May; 33 (5): 829–839. doi: 10.1016/s0272-6386(99)70414-2. PMID: 10213637.Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999 May; 33 (5): 829–839. doi: 10.1016/s0272-6386(99)70414-2. PMID: 10213637.Opelz G, Döhler B, Laux G. Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005 Apr; 5 (4 Pt 1): 720–728. doi: 10.1111/j.1600-6143.2004.00765.x. PMID: 15760395.Opelz G, Döhler B, Laux G. Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant. 2005 Apr; 5 (4 Pt 1): 720–728. doi: 10.1111/j.1600-6143.2004.00765.x. PMID: 15760395.Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 1993 Dec; 4 (6): 1300–1305. doi: 10.1681/ASN.V461300. PMID: 8130356.Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 1993 Dec; 4 (6): 1300–1305. doi: 10.1681/ASN.V461300. PMID: 8130356.Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010 Feb; 77 (4): 299–311. doi: 10.1038/ki.2009.377. Epub 2009 Oct 21. PMID: 19847156.Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010 Feb; 77 (4): 299–311. doi: 10.1038/ki.2009.377. Epub 2009 Oct 21. PMID: 19847156.Pascual J, Quereda C, Zamora J, Hernández D. Spanish Group for Evidence-Based Medicine in Renal Transplantation. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc. 2005 Nov; 37 (9): 3746–3748. doi: 10.1016/j.transproceed.2005.09.177. PMID: 16386525.Pascual J, Quereda C, Zamora J, Hernández D. Spanish Group for Evidence-Based Medicine in Renal Transplantation. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc. 2005 Nov; 37 (9): 3746–3748. doi: 10.1016/j.transproceed.2005.09.177. PMID: 16386525.Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. Transplantation. 2013 Dec 27; 96 (12): 1082–1088. doi: 10.1097/TP.0b013e3182a64db9. PMID: 24056618.Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. Transplantation. 2013 Dec 27; 96 (12): 1082–1088. doi: 10.1097/TP.0b013e3182a64db9. PMID: 24056618.Heemann U, Abramowicz D, Spasovski G, Vanholder R. European Renal Best Practice Work Group on Kidney Transplantation. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant. 2011 Jul; 26 (7): 2099–2106. doi: 10.1093/ndt/gfr169. Epub 2011 May 9. PMID: 21555392.Heemann U, Abramowicz D, Spasovski G, Vanholder R. European Renal Best Practice Work Group on Kidney Transplantation. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant. 2011 Jul; 26 (7): 2099–2106. doi: 10.1093/ndt/gfr169. Epub 2011 May 9. PMID: 21555392.Pascual J. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant. 2011 Dec; 16 (6): 600–605. doi: 10.1097/MOT.0b013e32834c23fa. PMID: 21971514.Pascual J. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant. 2011 Dec; 16 (6): 600–605. doi: 10.1097/MOT.0b013e32834c23fa. PMID: 21971514.Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012 Feb; 27 (2): 825–832. doi: 10.1093/ndt/gfr374. Epub 2011 Jul 22. PMID: 21785040.Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012 Feb; 27 (2): 825–832. doi: 10.1093/ndt/gfr374. Epub 2011 Jul 22. PMID: 21785040.Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant. 2009 Jan; 9 (1): 160–168. doi: 10.1111/j.1600-6143.2008.02442.x. Epub 2008 Oct 24. PMID: 18976304; PMCID: PMC2626128.Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant. 2009 Jan; 9 (1): 160–168. doi: 10.1111/j.1600-6143.2008.02442.x. Epub 2008 Oct 24. PMID: 18976304; PMCID: PMC2626128.Азатиоприн: инструкция по применению [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Azathioprine: instruction [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Elion GB. The purine path to chemotherapy. Science. 1989 Apr 7; 244 (4900): 41–47. doi: 10.1126/science.2649979. PMID: 2649979.Elion GB. The purine path to chemotherapy. Science. 1989 Apr 7; 244 (4900): 41–47. doi: 10.1126/science.2649979. PMID: 2649979.Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996 Aug 23; 273 (5278): 1109–1111. doi: 10.1126/science.273.5278.1109. PMID: 8688098.Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996 Aug 23; 273 (5278): 1109–1111. doi: 10.1126/science.273.5278.1109. PMID: 8688098.Karam S, Wali RK. Current State of Immunosuppression: Past, Present, and Future. Crit Rev Eukaryot Gene Expr. 2015; 25 (2): 113–134. doi: 10.1615/critreveukaryotgeneexpr.2015011421. PMID: 26080606.Karam S, Wali RK. Current State of Immunosuppression: Past, Present, and Future. Crit Rev Eukaryot Gene Expr. 2015; 25 (2): 113–134. doi: 10.1615/critreveukaryotgeneexpr.2015011421. PMID: 26080606.Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995 Aug 15; 60 (3): 225–232. doi: 10.1097/00007890-199508000-00003. PMID: 7645033.Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995 Aug 15; 60 (3): 225–232. doi: 10.1097/00007890-199508000-00003. PMID: 7645033.Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy. 1997 Nov-Dec; 17 (6): 1178–1197. PMID: 9399601.Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy. 1997 Nov-Dec; 17 (6): 1178–1197. PMID: 9399601.Микофенолата мофетил [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Микофенолата мофетил [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993 Dec 25; 268 (36): 27286–27290. PMID: 7903306.Mycophenolate mofetil [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991 Feb; 33 (2): 161–173. doi: 10.1111/j.1365-3083.1991. tb03746.x. PMID: 1826793.Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993 Dec 25; 268 (36): 27286–27290. PMID: 7903306.Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999 Feb-Mar; 31 (1–2): 1250–1252. doi: 10.1016/s0041-1345(98)01984-8. PMID: 10083559.Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991 Feb; 33 (2): 161–173. doi: 10.1111/j.1365-3083.1991. tb03746.x. PMID: 1826793.Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2003 Oct; 134 (1): 63–69. doi: 10.1046/j.1365-2249.2003.02269.x. PMID: 12974756; PMCID: PMC1808848.Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999 Feb-Mar; 31 (1–2): 1250–1252. doi: 10.1016/s0041-1345(98)01984-8. PMID: 10083559.Gonzalez Molina M, Seron D, Garcia del Moral R, Carrera M, Sola E, Jesus Alferez M et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation. 2004 Jan 27; 77 (2): 215–220. doi: 10.1097/01. TP.0000100684.59784.FF. PMID: 14742984.Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2003 Oct; 134 (1): 63–69. doi: 10.1046/j.1365-2249.2003.02269.x. PMID: 12974756; PMCID: PMC1808848.Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009 Mar 27; 87 (6): 785–794. doi: 10.1097/TP.0b013e3181952623. PMID: 19300178.Gonzalez Molina M, Seron D, Garcia del Moral R, Carrera M, Sola E, Jesus Alferez M et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation. 2004 Jan 27; 77 (2): 215–220. doi: 10.1097/01. TP.0000100684.59784.FF. PMID: 14742984.Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013 Dec 28; 19 (48): 9156–9173. doi: 10.3748/wjg.v19.i48.9156. PMID: 24409044; PMCID: PMC3882390.Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009 Mar 27; 87 (6): 785–794. doi: 10.1097/TP.0b013e3181952623. PMID: 19300178.Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978 Dec 23–30; 2 (8104-5): 1323–1327. doi: 10.1016/s0140-6736(78)91970-0. PMID: 82836.Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013 Dec 28; 19 (48): 9156–9173. doi: 10.3748/wjg.v19.i48.9156. PMID: 24409044; PMCID: PMC3882390.Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003 Feb; 3 (2): 178–185. doi: 10.1034/j.1600-6143.2003.00010.x. PMID: 12603213.Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978 Dec 23–30; 2 (8104-5): 1323–1327. doi: 10.1016/s0140-6736(78)91970-0. PMID: 82836.Гудкова ВВ, Кимельфельд ЕИ, Стаховская ЛВ. Малоизвестный синдром задней обратимой энцефалопатии, требующий неотложной помощи. Consilium Medicum. 2018; 20 (2): 84–89.Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003 Feb; 3 (2): 178–185. doi: 10.1034/j.1600-6143.2003.00010.x. PMID: 12603213.Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20; 357 (25): 2562–2575. doi: 10.1056/NEJMoa067411. PMID: 18094377.Gudkova VV, Kimel’fel’d EI, Stakhovskaya LV. Maloizvestnyy sindrom zadney obratimoy entsefalopatii, trebuyushchiy neotlozhnoy pomoshchi. Consilium Medicum. 2018; 20 (2): 84–89. doi: 10.26442/2075-1753_2018.2.84-89.Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009 Aug; 9 (8): 1876–1885. doi: 10.1111/j.1600-6143.2009.02726.x. Epub 2009 Jun 26. PMID: 19563339.Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20; 357 (25): 2562–2575. doi: 10.1056/NEJMoa067411. PMID: 18094377.Vézina C, Kudelski A, Sehgal SN. Rapmycin (AY- 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975 Oct; 28 (10): 721–726. doi: 10.7164/antibiotics.28.721. PMID: 1102508.Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009 Aug; 9 (8): 1876–1885. doi: 10.1111/j.1600-6143.2009.02726.x. Epub 2009 Jun 26. PMID: 19563339.Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004; 43 (2): 83–95. doi: 10.2165/00003088-200443020-00002. PMID: 14748618.Vézina C, Kudelski A, Sehgal SN. Rapmycin (AY- 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975 Oct; 28 (10): 721–726. doi: 10.7164/antibiotics.28.721. PMID: 1102508.Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by Rapmycin. Cell Immunol. 1994 Jul; 156 (2): 493–507. doi: 10.1006/cimm.1994.1193. PMID: 7517796.Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004; 43 (2): 83–95. doi: 10.2165/00003088-200443020-00002. PMID: 14748618.Kim HS, Raskova J, Degiannis D, Raska K Jr. Effects of cyclosporine and Rapmycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol. 1994 Jun; 96 (3): 508–512. doi: 10.1111/j.1365-2249.1994.tb06058.x. PMID: 8004821; PMCID: PMC1534564.Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by Rapmycin. Cell Immunol. 1994 Jul; 156 (2): 493–507. doi: 10.1006/cimm.1994.1193. PMID: 7517796.Ponticelli C. The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol. 2014 Feb; 10 (2): 295–305. doi: 10.1586/1744666X.2014.872562. Epub 2013 Dec 30. PMID: 24377908.Kim HS, Raskova J, Degiannis D, Raska K Jr. Effects of cyclosporine and Rapmycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol. 1994 Jun; 96 (3): 508–512. doi: 10.1111/j.1365-2249.1994.tb06058.x. PMID: 8004821; PMCID: PMC1534564.Viklický O, Zou H, Müller V, Lacha J, Szabó A, Heemann U. SDZ-RAD предотвращает проявление хронического отторжения у почечных аллотрансплантатов крыс. Пересадка. 2000 Фев 27; 69 (4): 497–502.Ponticelli C. The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol. 2014 Feb; 10 (2): 295–305. doi: 10.1586/1744666X.2014.872562. Epub 2013 Dec 30. PMID: 24377908.Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapmune US Study Group. Lancet. 2000 Jul 15; 356 (9225): 194–202. doi: 10.1016/s0140-6736(00)02480-6. PMID: 10963197.Viklický O, Zou H, Müller V, Lacha J, Szabó A, Heemann U. SDZ-RAD предотвращает проявление хронического отторжения у почечных аллотрансплантатов крыс. Пересадка. 2000 Фев 27; 69 (4): 497–502. Viklický O, Zou H, Müller V, Lacha J, Szabó A, Heemann U. SDZ-RAD predotvrashchaet proyavlenie khronicheskogo ottorzheniya u pochechnykh allotransplantatov krys. Peresadka. 2000 Fev 27; 69 (4): 497–502. doi: 10.1097/00007890-200002270-00006. PMID: 10708101.Garcia R, Machado PG, Felipe CR, Park SI, Spinelli GA, Franco MF et al. Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. Braz J Med Biol Res. 2007 Apr; 40 (4): 457–465. doi: 10.1590/s0100-879x2007000400003. PMID: 17401488.Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapmune US Study Group. Lancet. 2000 Jul 15; 356 (9225): 194–202. doi: 10.1016/s0140-6736(00)02480-6. PMID: 10963197.Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011 Apr; 79 (8): 897–907. doi: 10.1038/ki.2010.492. Epub 2010 Dec 29. PMID: 21191361.Garcia R, Machado PG, Felipe CR, Park SI, Spinelli GA, Franco MF et al. Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. Braz J Med Biol Res. 2007 Apr; 40 (4): 457–465. doi: 10.1590/s0100-879x2007000400003. PMID: 17401488.Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC et al. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009 Jan 27; 87 (2): 233–242. doi: 10.1097/TP.0b013e3181927a41. PMID: 19155978.Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011 Apr; 79 (8): 897–907. doi: 10.1038/ki.2010.492. Epub 2010 Dec 29. PMID: 21191361.Roman A, Ussetti P, Zurbano F, Borro JM, Solé A, Carreño MC, Santos F. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc. 2011 Sep; 43 (7): 2693–2698. doi: 10.1016/j.transproceed.2011.06.028. PMID: 21911148.Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC et al. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009 Jan 27; 87 (2): 233–242. doi: 10.1097/TP.0b013e3181927a41. PMID: 19155978.De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F et al. H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012 Nov; 12 (11): 3008–3020. doi: 10.1111/j.1600-6143.2012.04212.x. Epub 2012 Aug 6. PMID: 22882750; PMCID: PMC3533764.Roman A, Ussetti P, Zurbano F, Borro JM, Solé A, Carreño MC, Santos F. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc. 2011 Sep; 43 (7): 2693–2698. doi: 10.1016/j.transproceed.2011.06.028. PMID: 21911148.Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013 May; 13 (5): 1203–1216. doi: 10.1111/ajt.12181. Epub 2013 Feb 22. PMID: 23433101.De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F et al. H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012 Nov; 12 (11): 3008–3020. doi: 10.1111/j.1600-6143.2012.04212.x. Epub 2012 Aug 6. PMID: 22882750; PMCID: PMC3533764.Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH et al. Clinical experience of tacrolimus with everolimus in heart transplantation. Transplant Proc. 2012 May; 44 (4): 907–909. doi: 10.1016/j.transproceed.2012.01.094. PMID: 22564581.Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013 May; 13 (5): 1203–1216. doi: 10.1111/ajt.12181. Epub 2013 Feb 22. PMID: 23433101.LaMattina JC, Mezrich JD, Fernandez LA, D’Alessandro AM, Djamali A, Musat AI et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant. 2013 Mar-Apr; 27 (2): 193–202. doi: 10.1111/ctr.12063. Epub 2013 Jan 7. PMID: 23294013; PMCID: PMC3622762.Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH et al. Clinical experience of tacrolimus with everolimus in heart transplantation. Transplant Proc. 2012 May; 44 (4): 907–909. doi: 10.1016/j.transproceed.2012.01.094. PMID: 22564581.Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014 Mar; 14 (3): 701–710. doi: 10.1111/ajt.12615. Epub 2014 Feb 6. PMID: 24502384; PMCID: PMC4285226.LaMattina JC, Mezrich JD, Fernandez LA, D’Alessandro AM, Djamali A, Musat AI et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant. 2013 Mar-Apr; 27 (2): 193–202. doi: 10.1111/ctr.12063. Epub 2013 Jan 7. PMID: 23294013; PMCID: PMC3622762.Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer. 2012 Nov; 1 (3–4): 247–256. doi: 10.1159/000343839. PMID: 24159589; PMCID: PMC3760459.Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014 Mar; 14 (3): 701–710. doi: 10.1111/ajt.12615. Epub 2014 Feb 6. PMID: 24502384; PMCID: PMC4285226.Сушков АИ, Мойсюк ЯГ. Белатацепт при трансплантации почки. Вестник трансплантологии и искусственных органов. 2013; 15 (1): 96–105.Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer. 2012 Nov; 1 (3–4): 247–256. doi: 10.1159/000343839. PMID: 24159589; PMCID: PMC3760459.Белатацепт: описание [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Sushkov AI, Moysyuk YaG. Belatatsept pri transplantatsii pochki. Vestnik transplantologii i iskusstvennykh organov. 2013; 15 (1): 96–105. https://doi.org/10.15825/1995-1191-2013-1-96-105.Su VC, Harrison J, Rogers C, Ensom MH. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012 Jan; 46 (1): 57–67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. PMID: 22215686.Belatacept: description [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD et al. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. Clin Transplant. 2018 Apr; 32 (4): e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14. PMID: 29461660.Su VC, Harrison J, Rogers C, Ensom MH. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012 Jan; 46 (1): 57–67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. PMID: 22215686.Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar; 10 (3): 535–546. doi: 10.1111/j.1600-6143.2009.03005.x. PMID: 20415897.Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD et al. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. Clin Transplant. 2018 Apr; 32 (4): e13225. doi: 10.1111/ctr.13225. Epub 2018 Mar 14. PMID: 29461660.Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011 May 15; 91 (9): 976–983. doi: 10.1097/TP.0b013e31820c10eb. PMID: 21372756.Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar; 10 (3): 535–546. doi: 10.1111/j.1600-6143.2009.03005.x. PMID: 20415897.Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar; 10 (3): 547–557. doi:10.1111/j.1600-6143.2010.03016.x. PMID: 20415898.Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011 May 15; 91 (9): 976–983. doi: 10.1097/TP.0b013e31820c10eb. PMID: 21372756.Goring SM, Levy AR, Ghement I, Kalsekar A, Eyawo O, L’Italien GJ, Kasiske B. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr Med Res Opin. 2014 Aug; 30 (8): 1473–1487. doi: 10.1185/03007995.2014.898140. Epub 2014 Apr 3. PMID: 24628478.Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar; 10 (3): 547–557. doi:10.1111/j.1600-6143.2010.03016.x. PMID: 20415898.Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010 Dec 27; 90 (12): 1511–1515. doi: 10.1097/TP.0b013e3181fecfcb. PMID: 21057388.Goring SM, Levy AR, Ghement I, Kalsekar A, Eyawo O, L’Italien GJ, Kasiske B. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr Med Res Opin. 2014 Aug; 30 (8): 1473–1487. doi: 10.1185/03007995.2014.898140. Epub 2014 Apr 3. PMID: 24628478.Базиликсимаб [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 April 11]. Available from: https://www.vidal.ru/.Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010 Dec 27; 90 (12): 1511–1515. doi: 10.1097/TP.0b013e3181fecfcb. PMID: 21057388.2009 OPTN/SRTR annual report: transplant data 1999–2008 [report on the Internet]. Bethesda, MD: Health Resources and Services Administration, US Department of Health & Human Services; 2009 [cited 20 April 2015].Basiliximab [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 April 11]. Available from: https://www.vidal.ru/.Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L et al. OPTN/SRTR 2020 Annual Data Report: Kidney. Am J Transplant. 2022 Mar; 22 Suppl 2: 21–136. doi: 10.1111/ajt.16982. PMID: 35266618.2009 OPTN/SRTR annual report: transplant data 1999–2008 [report on the Internet]. Bethesda, MD: Health Resources and Services Administration, US Department of Health & Human Services; 2009 [cited 20 April 2015].Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients: how convincing is the current evidence? Drugs. 2012 Mar 26; 72 (5): 671–683. doi: 10.2165/11631300-000000000-00000. PMID: 22439670.Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L et al. OPTN/SRTR 2020 Annual Data Report: Kidney. Am J Transplant. 2022 Mar; 22 Suppl 2: 21–136. doi: 10.1111/ajt.16982. PMID: 35266618.Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003 Mar 15; 75 (5): 657–662. doi: 10.1097/01.TP.0000053198.99206.E6. PMID:12640305.Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients: how convincing is the current evidence? Drugs. 2012 Mar 26; 72 (5): 671–683. doi: 10.2165/11631300-000000000-00000. PMID: 22439670.Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008 Apr 1; 111 (7): 3675–3683. doi: 10.1182/blood-2008-01-130146. Epub 2008 Feb 4. PMID: 18250226; PMCID: PMC2275026.Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003 Mar 15; 75 (5): 657–662. doi: 10.1097/01.TP.0000053198.99206.E6. PMID:12640305.Жулай ГА, Олейник ЕК. Регуляторные Т-лимфоциты CD4+CD25+FOXP3+. Перспективы применения в иммунотерапии. Труды Карельского научного центра РАН. 2012; 2: 3–17.Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008 Apr 1; 111 (7): 3675–3683. doi: 10.1182/blood-2008-01-130146. Epub 2008 Feb 4. PMID: 18250226; PMCID: PMC2275026.Urbanova M, Brabcova I, Girmanova E, Zelezny F, Viklicky O. Differential regulation of the nuclear factor-κB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation. 2012 Mar 27; 93 (6): 589–596. doi: 10.1097/TP.0b013e31824491aa. PMID: 22334040.Zhulay GA, Oleynik EK. Regulyatornye T-limfotsity CD4+CD25+FOXP3+. Perspektivy primeneniya v immunoterapii. Trudy Karel’skogo nauchnogo tsentra RAN. 2012; 2: 3–17.Тимоглобулин: инструкция по применению [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from:Urbanova M, Brabcova I, Girmanova E, Zelezny F, Viklicky O. Differential regulation of the nuclear factor-κB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation. 2012 Mar 27; 93 (6): 589–596. doi: 10.1097/TP.0b013e31824491aa. PMID: 22334040.https://www.vidal.ru/.Thymoglobulin: instruction [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009 Jul 30; 69 (11): 1483–1512. doi: 10.2165/00003495-200969110-00007. PMID: 19634926.Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009 Jul 30; 69 (11): 1483–1512. doi: 10.2165/00003495-200969110-00007. PMID: 19634926.Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006 Nov 9; 355 (19): 1967–1977. doi: 10.1056/NEJMoa060068. PMID: 17093248.Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006 Nov 9; 355 (19): 1967–1977. doi: 10.1056/NEJMoa060068. PMID: 17093248.Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P et al. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. 2004; 27 (2): 91–106. doi: 10.2165/00002018-200427020-00002. PMID: 14717621.Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P et al. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. 2004; 27 (2): 91–106. doi: 10.2165/00002018-200427020-00002. PMID: 14717621.Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L et al. Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003 Jan 15; 75 (1): 37–43. doi: 10.1097/00007890-200301150-00007. PMID: 12544868.Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L et al. Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003 Jan 15; 75 (1): 37–43. doi: 10.1097/00007890-200301150-00007. PMID: 12544868.Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K et al. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab. Cell Transplant. 2012; 21 (2–3): 565–570. doi: 10.3727/096368911X605493. PMID: 22793066.Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K et al. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab. Cell Transplant. 2012; 21 (2–3): 565–570. doi: 10.3727/096368911X605493. PMID: 22793066.Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000 Mar 2; 342 (9): 613–619. doi: 10.1056/NEJM200003023420902. PMID: 10699160.Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000 Mar 2; 342 (9): 613–619. doi: 10.1056/NEJM200003023420902. PMID: 10699160.Алемтузумаб [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 April 11]. Available from: https://www.vidal.ru/.Alemtuzumab [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 April 11]. Available from: https://www.vidal.ru/.Prasad N, Gurjer D, Bhadauria D, Gupta A, Srivastava A, Kaul A et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology (Carlton). 2014 Apr; 19 (4): 244–250. doi: 10.1111/nep.12209. PMID: 24447227.Prasad N, Gurjer D, Bhadauria D, Gupta A, Srivastava A, Kaul A et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology (Carlton). 2014 Apr; 19 (4): 244–250. doi: 10.1111/nep.12209. PMID: 24447227.Morris PJ, Russell NK. Alemtuzumab (Campath- 1H): a systematic review in organ transplantation. Transplantation. 2006 May 27; 81 (10): 1361–1367. doi: 10.1097/01.tp.0000219235.97036.9c. PMID: 16732169.Morris PJ, Russell NK. Alemtuzumab (Campath- 1H): a systematic review in organ transplantation. Transplantation. 2006 May 27; 81 (10): 1361–1367. doi: 10.1097/01.tp.0000219235.97036.9c. PMID: 16732169.Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998 Jun 6; 351 (9117): 1701–1702. doi: 10.1016/S0140-6736(05)77739-4. Erratum in: Lancet 1998 Aug 1; 352 (9125): 408. PMID: 9734890.Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998 Jun 6; 351 (9117): 1701–1702. doi: 10.1016/S0140-6736(05)77739-4. Erratum in: Lancet 1998 Aug 1; 352 (9125): 408. PMID: 9734890.Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15; 76 (1): 120–129. doi: 10.1097/01.TP.0000071362.99021.D9. PMID: 12865797.Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15; 76 (1): 120–129. doi: 10.1097/01.TP.0000071362.99021.D9. PMID: 12865797.Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR et al. INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011 May 19; 364 (20): 1909–1919. doi: 10.1056/NEJMoa1009546. PMID: 21591943.Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR et al. INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011 May 19; 364 (20): 1909–1919. doi: 10.1056/NEJMoa1009546. PMID: 21591943.LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D’Alessandro AM, Sollinger HW, Pirsch JD. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int. 2012 May; 25 (5): 518–526. doi: 10.1111/j.1432-2277.2012.01448.x. Epub 2012 Mar 6. PMID: 22394259; PMCID: PMC3665410.LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D’Alessandro AM, Sollinger HW, Pirsch JD. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int. 2012 May; 25 (5): 518–526. doi: 10.1111/j.1432-2277.2012.01448.x. Epub 2012 Mar 6. PMID: 22394259; PMCID: PMC3665410.Hurst FP, Altieri M, Nee R, Agodoa LY, Abbott KC, Jindal RM. Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol. 2011; 34 (6): 534–541. doi: 10.1159/000334092. Epub 2011 Nov 18. PMID: 22104284; PMCID: PMC3237278.Hurst FP, Altieri M, Nee R, Agodoa LY, Abbott KC, Jindal RM. Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol. 2011; 34 (6): 534–541. doi: 10.1159/000334092. Epub 2011 Nov 18. PMID: 22104284; PMCID: PMC3237278.Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB et al. Campath-1H induction plus Rapmycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003 Jun; 3 (6): 722–730. doi: 10.1034/j.1600-6143.2003.00120.x. PMID: 12780564.Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB et al. Campath-1H induction plus Rapmycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003 Jun; 3 (6): 722–730. doi: 10.1034/j.1600-6143.2003.00120.x. PMID: 12780564.Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant. 2005 Dec; 5 (12): 3009– 3014. doi: 10.1111/j.1600-6143.2005.01123.x. PMID: 16303017.Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant. 2005 Dec; 5 (12): 3009– 3014. doi: 10.1111/j.1600-6143.2005.01123.x. PMID: 16303017.Ритуксимаб [Internet]. Vidal: Cправочник лекарственных средств; с2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/. Rituximab [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Rituximab [Internet]. Vidal: Spravochnik lekarstvennyh sredstv; s2020-09 [Updated 2022 July 11]. Available from: https://www.vidal.ru/.Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17; 359 (3): 242–251. doi: 10.1056/NEJMoa0707894. PMID: 18635429.Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17; 359 (3): 242–251. doi: 10.1056/NEJMoa0707894. PMID: 18635429.Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A et al. The 5-year outcome of AB0-incompatible kidney transplantation with rituximab induction. Transplantation. 2011 Apr 27; 91 (8): 853–857. doi: 10.1097/TP.0b013e31820f08e8. PMID: 21297552.Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A et al. The 5-year outcome of AB0-incompatible kidney transplantation with rituximab induction. Transplantation. 2011 Apr 27; 91 (8): 853–857. doi: 10.1097/TP.0b013e31820f08e8. PMID: 21297552.Столяревич ЕС, Артюхина ЛЮ, Иванова ЕС, Томилина НА. Использование комбинированной терапии плазмаферезом, внутривенным человеческим иммуноглобулином и ритуксимабом для лечения хронического отторжения трансплантированной почки. Нефрология. 2016; 20 (6): 67–74.Stolyarevich ES, Artyukhina LYu, Ivanova ES, Tomilina NA. Ispol’zovanie kombinirovannoy terapii plazmaferezom, vnutrivennym chelovecheskim immunoglobulinom i rituksimabom dlya lecheniya khronicheskogo ottorzheniya transplantirovannoy pochki. Nefrologiya. 2016; 20 (6): 67–74.Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009 May 15; 87 (9): 1325–1329. doi: 10.1097/TP.0b013e3181a235fd. PMID: 19424032.Tydén G, Genberg H, Tollemar J, Ekberg H, Persson NH, Tufveson G et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009 May 15; 87 (9): 1325–1329. doi: 10.1097/TP.0b013e3181a235fd. PMID: 19424032.Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, Smith KG. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009 Jun 18; 360 (25): 2683–2685. doi: 10.1056/NEJMc0808481. PMID: 19535812; PMCID: PMC4143588.Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, Smith KG. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009 Jun 18; 360 (25): 2683–2685. doi: 10.1056/NEJMc0808481. PMID: 19535812; PMCID: PMC4143588.

The authors declare that there are no conflicts of interest present.